ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone

Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further benefits gained from the addition of the PARP inhibitor olaparib in maintenance setting, according to researchers from The University of Texas MD Anderson Cancer Center.

Divisive democracy and constitutionalism

THE importance of our constitution as a fundamental framework for governance cannot be overstate. This doctrine simply means that Government power should be limited, structured and subjected to the rule of law.

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.


Q&A: The art of diabetes care—why precision medicine leads to better diabetes care

Diabetes can show up in almost anyone: pregnant women, babies, kids, teens, adults both young and old. But the condition’s various forms, all of which affect how the body processes blood sugar, can manifest quite differently in the hundreds of millions of people worldwide who have the disease—making it perfect for the individualized approach known as precision medicine, Stanford Medicine researchers say.

Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers

Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial cancers with FGFR alterations. Results from the Phase III THOR trial, led by researchers at The University of Texas MD Anderson Cancer Center, were reported at the 2023 European Society of Medical Oncology (ESMO) Congress.